AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Learn how the wash sale rule impacts dividend ETFs in 2024 and what it means for your taxable gains. This quick intro covers key considerations and practical implications for DIY investors.
28,052 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
A top exec recently sold a sizable block of Freshpet shares. This article breaks down what insider selling means, how...
A CFO selling NuScale stock can spark questions about the company’s outlook. This guide breaks down what the move mig...
Looking to turn a $2,000 stake into steady income? This guide breaks down the smartest dividend with $2,000, how to p...
When a former chief officer sells stock, investors should look beyond the headline. This guide explains why insider m...
Insider sales by a bank CEO can raise questions. This article breaks down what a move like 'live bancshares sells ano...
Insider moves can reveal clues about a company's near-term prospects. This article dives into the remitly director's ...
Looking for a simple, reliable path to steady income? This no-brainer dividend right passive approach centers on a hi...
If you’re hunting for reliable dividend income, AbbVie and Pfizer are two top contenders. This guide breaks down whic...
A single rental property sale can push Medicare premiums higher for two years due to a two-year MAGI lookback, compli...
When a company's top executive sells a large chunk of stock, investors take note. This article dives into Privia Heal...
A big trade in a technology-focused ETF last quarter offers more than a headline. This article digs into what investo...